Why Kratom Paradise Does Not Sell Synthetic 7-OH

Kratom Paradise does not sell synthetic or concentrated 7-OH products. The catalog is built around plain kratom leaf, clearly identified MIT products, and a separate kava line.

Elevated 7-OH is not ordinary leaf

7-hydroxymitragynine occurs at low levels in natural Mitragyna speciosa leaf. Concentration, chemical conversion, or synthesis can make 7-OH the defining active in a manufactured product and create an exposure very different from milled leaf.

Concentrated 7-OH is opioid-active and can involve sedation, tolerance, dependence, withdrawal, interactions, and respiratory risk. It should not be folded into the botanical-leaf category simply because its chemistry traces back to kratom.

Why Kratom Paradise draws the line here

A product should state its active compound plainly and be supported by records that match the material or finished item being sold. The 7-OH market has developed faster than consistent formulation, labeling, research, and regulation. Kratom Paradise has chosen not to make those products part of its range.

The exclusion also covers mitragynine pseudoindoxyl (MGPI), MGM-15, MGM-16, and products marketed through pain-treatment, opioid-withdrawal, or effect-replacement claims.

MIT remains a separate category

MIT means mitragynine. Kratom Paradise's MIT tablets and extract powder identify mitragynine as the relevant active and link the available laboratory record to the corresponding product or source material. MIT and 7-OH are distinct compounds, and their milligram figures do not provide an effect-equivalence conversion.

Current federal position

MGPI, MGM-15, and MGM-16 became temporarily Schedule I on August 26, 2026. DEA's separate threshold proposal for 7-OH remained pending as of September 19, 2026. State laws and delivery rules may be narrower.

Shop Kratom Paradise products · Review MIT documents · Read FDA's 7-OH overview